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Abstract
Background and Aim: Concomitant therapy is a recommended first-line treatment for
Helicobacter pylori infection in most national or international consensuses. Reverse hybrid
therapy is a modified 14-day concomitant therapy without clarithromycin and metronida-
zole in the final 7 days. This study aims to test whether 14-day reverse hybrid therapy is
non-inferior to 14-day concomitant therapy in the first-line treatment of H. pylori infection.
Methods: Helicobacter pylori-infected adult patients were randomly assigned to receive
either reverse hybrid therapy (dexlansoprazole 60 mg o.d. plus amoxicillin 1 g b.d. for
14 days, and clarithromycin 500 mg plus metronidazole 500 mg b.d. for initial 7 days)
or concomitant therapy (dexlansoprazole 60 mg once o.d. plus amoxicillin 1 g,
clarithromycin 500 mg, and metronidazole 500 mg b.d. for 14 days). H. pylori status
was assessed 6 weeks after the end of treatment.
Results: Helicobacter pylori-infected participants (n = 248) were randomized to receive ei-
ther 14-day reverse hybrid therapy (n = 124) or 14-day concomitant therapy (n = 124).
Intention-to-treat analysis demonstrated that the two therapies had comparable eradication
rate (95.2% vs 93.5%; 95% confidence interval, 4.0% to 7.4%; P = 0.582). However, re-
verse hybrid therapy had a much lower frequency of adverse events than concomitant ther-
apy (20.2% vs 38.7%, P = 0.001). The two therapies exhibited comparable drug adherence
(93.5% vs 87.9%, P = 0.125).
Conclusions: Fourteen-day reverse hybrid therapy and 14-day concomitant therapy are
equivalent in efficacy for the first-line treatment of H. pylori infection. However, reverse
hybrid therapy has fewer adverse events compared with concomitant therapy.
Introduction
With the rising prevalence of antimicrobial resistance, the eradica-
tion rates of standard triple therapy for Helicobacter pylori infec-
tion have declined to less than 80% in most countries.1, 2 Several
strategies including bismuth-containing quadruple therapy and
non-bismuth-containing quadruple therapy (i.e. sequential therapy,
concomitant therapy, and hybrid therapy) have been proposed to
increase the eradication rates.3–6
Concomitant therapy is an effective regimen with proven suc-
cess regardless of clarithromycin resistance in several studies.7, 8
It is a 4-drug regimen containing proton pump inhibitor (PPI),
clarithromycin, amoxicillin, and metronidazole, which are all
given for the entire duration of therapy. A meta-analysis demon-
strated that concomitant therapy is more effective than standard tri-
ple therapy.9 We recently developed hybrid therapy consisting of a
dual therapy with a PPI and amoxicillin for 7 days followed by a
quadruple regimen with a PPI, amoxicillin, clarithromycin, and
metronidazole for 7 days.5 A pilot study of hybrid therapy showed
that it achieved an eradication rate of 97.4% by intention-to-treat
(ITT) analysis and 99.1% by per-protocol (PP) analysis in
Taiwan.5 A subsequent randomized controlled trial from Iran, an
area with high clarithromycin resistance, demonstrated that
14-day hybrid therapy achieved a higher eradication rate than
14-day standard triple therapy.10 Several randomized controlled
trials demonstrated that 14-day hybrid therapies were comparable
or more effective than 10-day sequential therapies.11–15 A recent
large multicenter randomized controlled trial documented that
14-day hybrid and 14-day bismuth quadruple therapies had com-
parable efficacy in the treatment of H. pylori infection, and both
could cure more than 90% of patients with H. pylori infections
in areas of moderate clarithromycin resistance (17%).16 Currently,
doi:10.1111/jgh.15034
1731Journal of Gastroenterology and Hepatology 35 (2020) 1731–1737
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
bs_bs_banner
it is a recommended first-line treatment in the ACG guideline on
the treatment of H. pylori infection.17 Additionally, it is also a rec-
ommended first-line treatment option on the Bangkok Consensus
Report on H. pylori management in ASEAN.18 In the Taiwan
H. pylori Consensus Report, it is the treatment of choice in areas
with either high or low clarithromycin resistance.19
Nonetheless, hybrid therapy requires additional two antibiotics
in the last 7 days of therapy, which may confuse patients and
may dampen enthusiasm for its use in clinical practice. Reversing
the sequence of drug administration (a quadruple regimen
followed by a dual regimen) can simplify hybrid therapy so that
it is not necessary for patients to take additional medications dur-
ing the course of treatment. A pilot randomized trial demonstrated
that 12-day reverse hybrid therapy was more effective than 12-day
standard triple therapy in the first-line treatment of H. pylori
infection.20 A subsequent multicenter randomized controlled trial
showed that 14-day reverse hybrid and bismuth quadruple thera-
pies had comparable efficacy in the treatment of H. pylori infec-
tion, and both could cure more than 90% of patients with
H. pylori infections in a population with a clarithromycin resis-
tance rate of 14%.21
Basically, 14-day reverse hybrid therapy is a 14-day concomi-
tant therapy without clarithromycin and metronidazole in the final
7 days. Current evidences showed that 7-day concomitant quadru-
ple therapy achieves a high eradication rate for
clarithromycin-sensitive strains.7, 8 It remains unclear whether ex-
tending the treatment durations of clarithromycin and metronida-
zole of concomitant therapy from 7 to 14 days can improve the
eradication rate for H. pylori strains with clarithromycin resistance
or clarithromycin–metronidazole dual resistance. We therefore
conducted the randomized controlled trial to prove our hypothesis
that 14-day reverse hybrid therapy is non-inferior to 14-day con-
comitant therapy in the first-line treatment of H. pylori infection.
Additionally, we also compared the side effect profiles of the
two treatment strategies in this trial.
Methods
Study population. For this randomized, open-label trial,
non-inferiority phase 3 trial, we recruited H. pylori-infected adult
patients (age > 20 years) who underwent an
esophagogastroduodenoscopy for the investigation of gastrointes-
tinal symptoms in the Kaohsiung Veterans General Hospital and
Kaohsiung Medical University Hospital. H. pylori infection was
documented by at least two positive results of rapid urease test,
histology, urea breath test, and culture. Additionally, individuals
who underwent H. pylori screening with a positive result of both
13C-urea breath test and H. pylori serological testing were also in-
cluded for the study. Subjects with any of the following criteria
were excluded from this trial: (i) previous eradication therapy,
(ii) allergy to any antibiotic of our study, (iii) previous gastrec-
tomy, (iv) the coexistence of severe concomitant illness, (v) preg-
nancy or lactating women, and (vi) the use of antibiotics within the
previous 4 weeks.22
Written informed consent was obtained for all patients before
enrollment. This trial was approved by the Institutional Review
Boards of the Kaohsiung Veterans General Hospital and
Kaohsiung Medical University Hospital. It is registered as a
standard randomized Clinical Trial (ClinicalTrials.gov identifier:
NCT02646332). All authors had access to the study data and
had approved the final manuscript.
Study protocol
Randomization. Using a permuted block randomization with a
block size of four, we randomly allocated eligible patients to re-
ceive one of the two regimens (1:1): 14-day reverse hybrid or
14-day concomitant therapy. An independent research assistant
generated the computerized random number sequence. The se-
quence was concealed in an opaque envelope until the intervention
was assigned. All clinical investigators were masked to the ran-
domization sequence. After the written informed consents were
obtained from eligible subjects, study nurses telephoned indepen-
dent research assistant who then informed the patient’s treatment
allocation.
Procedures. The recruited patients received either a 14-day re-
verse hybrid therapy (dexlansoprazole MR [Dexilant delayed re-
lease; Takeda, Osaka, Japan] 60 mg once daily plus amoxicillin
1 g twice daily for 14 days, and clarithromycin 500 mg plus met-
ronidazole 500 mg twice daily for initial 7 days) or a 14-day con-
comitant therapy (dexlansoprazole MR 60 mg once daily plus
amoxicillin 1 g, clarithromycin 500 mg and metronidazole
500 mg twice daily for 14 days). All drugs were taken 1 h before
breakfast or dinner. Alcohol consumption during treatment was
prohibited as it may impact metronidazole-related side effects.
A complete medical history and demographic were obtained
from each patient, including age, sex, medical history, history of
smoking, and alcohol, coffee, and tea consumption at enrollment.
Additionally, blood sampling for genotyping of CYP2C19 and
IL-1β-511 was performed using the polymerase chain
reaction-restriction fragment length polymorphism as previous
description.23, 24 Genotypes of CYP2C19 were classified into three
groups: homogeneous extensive metabolizer (CYP2C19*1/
CYP2C19*1); heterogeneous extensive metabolizer
(CYP2C19*1/CYP2C19*2 and CYP2C19*1/CYP2C19*3); and
poor metabolizer (CYP2C19*2/CYP2C19*2, CYP2C19*2/
CYP2C19*3, and CYP2C19*3/CYP2C19*3). IL-1β-511 polymor-
phisms were classified as CC, CT, and TT genotypes. The biopsy
specimens were cultured on Brucella chocolate agar with 7%
sheep blood and incubated for 7 days under microaerobic condi-
tion. The antibiotic susceptibility of H. pylori strains was deter-
mined by E-test (AB Biodisk, Solna, Sweden) in the central
laboratory in the Kaohsiung Medical University Hospital.H. pylori
strains with a minimal inhibitory concentration value > 0.5, > 1,
and > 8 μg/mL were considered to be resistant to clarithromycin,
amoxicillin, and metronidazole, respectively.21, 24
Drug adherence and adverse events were recorded at week 2 of
therapy. All participants were informed of the common side effects
of the study drugs before treatment and were asked to record these
symptoms in the provided diaries. Participants with gastric ulcer
on enrollment received a follow-up endoscopy with rapid urease
test, histological examination, and bacterial culture to assess ulcer
healing and post-treatment H. pylori status 6 weeks after the end of
eradication therapy. The other subjects underwent a urea breath
test to assess H. pylori eradication 6 weeks following therapy
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ending. H. pylori eradication was defined as (i) a negative result of
urea breath test or (ii) negative results of all histology, rapid urease
test, and bacterial culture.24, 25 All participants were asked to dis-
continue PPI and histamine-2 blocker for at least 2 weeks before
follow-up endoscopy and urea breath testing. 13C-urea breath test
was performed after an overnight fast using the Proto Pylori kit
(Isodiagnostika, Montreal, Canada). The 75-mg 13C-urea was dis-
solved in water. Baseline and 30-min breath samples were assayed
with an infrared spectrometer that produced computer-generated
results in the Kaohsiung Veterans General Hospital and Kaohsiung
Medical University Hospital. Positive results were defined as a
computer-generated δ13CO2 value ≥ 4 units and negative results
as < 2.5 units.24 The subjects with inconclusive results underwent
another 13C-urea breath test at least 4 weeks later until the results
became conclusive. The technicians carrying out urea breath test
were blinded to the eradication regimens received by patients.
End points. The primary outcome was H. pylori eradication. The
secondary outcomes were the frequencies of adverse events and
drug adherence. Adverse events were prospectively assessed ac-
cording to a 4-point scale system: none; mild (discomfort annoy-
ing but not interfering with daily life); moderate (discomfort
sufficient to interfere with daily life); and severe (discomfort
resulting in discontinuation of eradication therapy).26 Drug adher-
ence was checked by counting unused medication at the comple-
tion of treatment. Poor adherence was defined as taking less than
80% of pills in the concomitant group. In the hybrid group, poor
compliance was defined as taking less than 80% of pills in either
initial 7 days or the last 7 days.27
Statistical analysis. Our study was designed as a
non-inferiority trial. The hypothesis for sample size calculations
was based on 94% eradication rate of reverse hybrid therapy and
95% eradication rate of concomitant therapy 15, 16, 21, 27 defining
non-inferiority 10%, expected power of 90% and a one-sided
95% confidence interval. One hundred ten patients per group
(completers) were needed to show non-inferiority of the experi-
mental therapy versus active control treatment. An estimated
10% of patients would not be included in the PP analysis because
of one or more major protocol deviations; therefore, at least 124
patients randomly assigned treatment per group were planned to
protect the trial’s power. Eradication rate was assessed by ITT,
modified ITT, and PP. The ITT population included all randomized
patients who receive at least one dose of study drugs. Patients
whose infection status was unknown following treatment were
considered treatment failures for the purposes of ITT analysis.
Modified ITT included all those receiving at least one dose of
drugs and completing post-treatment H. pylori testing. The PP
analysis excludes the patients with unknown H. pylori status fol-
lowing therapy and those with poor drug adherence. The 95% con-
fidence interval (CI) of the eradication rate of each therapy was
calculated. The χ2 test or Fisher’s exact test was used to analyze
categorical data. Student’s t test was used to analyze continuous
variables and give results as mean ± SD. A P value less than
0.05 was considered statistically significant. Statistic Package for
the Social Science (version 12.0 for Microsoft Windows) was used
for all statistical analyses.
Results
Characteristics of the study groups. From July 2016
to August 2108, 1091 patients were screened for eligibility.
Among them, 248 H. pylori-infected patients were eligible and
randomly allocated to receive either reverse hybrid (n = 124)
or concomitant (n = 124) therapy (Fig. 1). Data regarding the
clinical characteristics of patients upon entry are summarized
in Table 1. The two groups had comparable age, gender, history
of smoking, alcohol drinking, coffee and tea consumption, pres-
ence of peptic ulcers, and CYP2C19 and IL-1β-511 genotypes.
The two study groups also had a similar prevalence of antibiotic
resistant strains (Table 1). Among the subjects, 8 patients in the
reverse hybrid group and 18 in the concomitant group were ex-
cluded from PP analysis due to incomplete follow-up or poor
adherence (Fig. 1).
Eradication of Helicobacter pylori. Table 2 lists the
eradication rates of the two therapies. ITT analysis showed that
the eradication rates were 95.2% (95% CI, 91.4% to 99.0%)
for reverse hybrid therapy and 93.5% (95% CI, 89.2% to
97.8%) for concomitant therapy. We recorded no statistically
significant differences in treatment efficacy between the two
therapies (difference, 1.7%; 95% CI, 4.0% to 7.4%;
P = 0.582). Modified ITT (95.2% vs 95.0%) and PP analyses
(95.7% vs 93.6%) yielded similar results (P = 0.965 and
0.481, respectively). Among the subjects with drug susceptibility
data, the eradication rates of hybrid therapy for H. pylori strains
with non-resistance, single clarithromycin resistance, single met-
ronidazole resistance, and dual resistances were 100% (20/20),
100% (4/4), 100% (9/9), and 100% (1/1), respectively. In the
concomitant therapy group, the eradication rates for H. pylori
strains with non-resistance, single clarithromycin resistance, sin-
gle metronidazole resistance, and dual resistances were 100%
(18/18), 80% (4/5), 100% (12/12), and 100% (4/4), respectively.
No differences in eradication rates between reverse hybrid ther-
apy and concomitant therapy existed in the four subgroups of
H. pylori strains.
Adverse events and adherences. All the patients were
included in the ITT analysis for adverse events and drug adher-
ences. The frequencies of adverse events in the participants re-
ceiving 14-day reverse hybrid and 14-day concomitant
therapies were 20.2% (95% CI, 14.9% to 27.3%) and 38.7%
(95% CI, 30.1% to 47.3%), respectively. The former had fewer
adverse events than the latter (difference, 16.7%; 95% CI,
27.8% to 5.6%; P = 0.001). Table 3 lists the profiles of ad-
verse events of 14-day reverse hybrid and 14-day concomitant
therapies. The reverse hybrid group had lower frequencies of ab-
dominal pain (4.0% vs 18.5%) and taste perversion (2.4% vs
11.3%) than the concomitant group (P < 0.001 and
P = 0.010, respectively). In the reverse hybrid group, eight pa-
tients discontinued treatment owing to adverse events (diarrhea:
three patients; nausea: one patient; abdominal pain: one patient;
headache: one patient; fever: one patient; and skin rash: one pa-
tient). Fifteen patients in the concomitant group stopped the
anti-H. pylori medication because of adverse events (diarrhea:
three patients; nausea: one patient; abdominal pain: four
P-I Hsu et al. Reverse hybrid and concomitant therapies
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patients; taste perversion: one patient; cold sweating: one pa-
tient; and skin rash: five patients). The two treatment groups
displayed similar adherence (93.5% vs 87.9%) (difference,
5.6%; 95% CI, 1.6% to 12.7%; P = 0.125).
Factors affecting the efficacy of anti-Helicobacter
pylori therapy. Table 4 lists the factors affecting the eradica-
tion rates of anti-H. pylori therapies. In the 14-day reverse hybrid
group, there were no clinical, genetic, or bacterial factors signifi-
cantly related to eradication efficacy. In the concomitant group,
all factors including CYP2C19 genotype, IL-1β-511 genotype,
smoking, alcohol drinking, drug adherence, and antibiotic resis-
tance also did not affect eradication efficacy (Table 4).
Discussion
In the current study, we conducted the first, head-to-head, random-
ized, controlled trial to compare the efficacies of 14-day reverse
hybrid and 14-day concomitant therapies for the first-line treat-
ment of H. pylori infection. The results demonstrated several novel
findings. First, the two therapies were equivalent in efficacy, cur-
ing most H. pylori-infected patients in an area of moderate
clarithromycin resistance (19.2%). Second, 14-day reverse hybrid
therapy exhibited a lower frequency of adverse events than
Figure 1 Disposition of patients. H. pylori, Helicobacter pylori; ITT, intention-to-treat; PP, per-protocol.
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14-day concomitant therapy (20.2% vs 38.7%; P = 0.001). Third,
the two therapies had comparable drug adherence (93.5% vs
87.9%; P = 0.125).
Recent studies showed that 7-day concomitant quadruple ther-
apy achieved a high eradication rate for H. pylori strains with
non-resistance, single clarithromycin resistance, or single metroni-
dazole resistance but had a low eradication efficacy for
clarithromycin–metronidazole dual resistance (50%).8, 9, 28 Theo-
retically, it is ineffective to extend the duration of clarithromycin
or metronidazole to 14 days to improve eradication efficacy of
concomitant regimen for clarithromycin–metronidazole dual resis-
tant strains. Therefore, 14-day reverse hybrid therapy applies
amoxicillin, clarithromycin, and metronidazole in the initial 7 days
of the regimen and only contains amoxicillin in the final 7 days of
treatment. The current study proved our hypothesis that 14-day re-
verse hybrid and 14-day concomitant therapies have comparable
eradication efficacy in the first-line treatment of H. pylori
infection.
Antibiotic resistance is the key factor in predicting eradication
outcome of anti-H. pylori therapy with standard triple therapy
and sequential therapy.29 In this study, antibiotic susceptibility
data were only available in 73 H. pylori stains. Nonetheless, one
of our previous studies provided large data assessing the impacts
of antibiotic resistances on the eradication rates of 14-day reverse
hybrid therapy (n = 107). According to the combination data of the
two studies, the eradication rates of reverse hybrid therapy for
H. pylori strains with non-resistance, single clarithromycin resis-
tance, single metronidazole resistance, and dual resistances were
98.8% (85/86), 92.9% (14/15), 100% (33/33), and 85.7% (6/7), re-
spectively. The results indicated that 14-day reverse hybrid
Table 1 Demographic data and antibiotic resistance of 14-day reverse hybrid and 14-day concomitant therapies
Characteristics Reverse hybrid therapy (n = 124) Concomitant therapy (n = 124) P value
Age (years) (mean ± SD) 56.1 ± 12.3 54.7 ± 11.2 0.368
Gender (male/female) 58/66 60/64 0.799
Smoking 18 (14.5%) 26 (21.0%) 0.184
Alcohol consumption 7 (5.6%) 5 (4.0%) 0.554
Ingestion of coffee 29 (23.4%) 35 (28.2%) 0.384
Ingestion of tea 32 (25.8%) 33 (26.6%) 0.885
Peptic ulcer disease 62 (50.0%) 56 (45.2%) 0.446
CYP2C19 genotype 0.753
HomEM 40/111 (36.0%) 36/115 (31.3%)
HetEM 43/111 (38.7%) 48/115 (41.7%)
PM 28/111 (25.2%) 31/115 (27.0%)
IL1-β genotype 0.570
CC 33/111 (29.7%) 33/115 (28.7%)
CT 51/111 (45.9%) 47/115 (40.0%)
TT 27/111 (24.3%) 35/115 (30.0%)
Prevalence of antibiotic resistance
Clarithromycin resistance 5/34 (14.7%) 9/39 (23.1%) 0.365
Metronidazole resistance 10/34 (29.4%) 16/39 (41.0%) 0.301
Amoxicillin resistance 0/34 (0%) 0/39 (0%) —
HetEM, heterogeneous extensive metabolizer; HomEM, homogeneous extensive metabolizer; PM, poor metabolizer.
Table 2 The major outcomes of 14-day reverse hybrid and 14-day concomitant therapies
Eradication rate Reverse hybrid therapy (n = 124) Concomitant therapy (n = 124) P value
Intention-to-treat analysis 95.2% (118/124) (91.4% to 99.0%)† 93.5% (116/124) (89.2% to 97.8%)† 0.582
Modified intention-to-treat analysis 95.2% (118/124) (91.4% to 99.0%)† 95.0% (115/121) (91.1% to 98.9%)† 0.965
Per-protocol analysis 95.7% (111/116) (92.0% to 99.4%)† 93.6% (102/109) (89.0% to 98.2%)† 0.481
†95% confidence interval.
Table 3 Adverse events of 14-day reverse hybrid and 14-day concom-
itant therapies
Adverse events Reverse hybrid
therapy (n = 124)
Concomitant
therapy (n = 124)
P value
Any adverse events 25 (20.2%) 48 (38.7%) 0.001*
Abdominal pain 5 (4.0%) 23 (18.5%) < 0.001*
Constipation 0 (%) 0 (0%) —
Diarrhea 6 (4.8%) 6 (4.8%) 0.989
Dizziness 2 (1.6%) 5 (4.0%) 0.446
Taste perversion 3 (2.4%) 14 (11.3%) 0.010*
Headache 1 (0.8%) 1 (0.8%) 1.000
Nausea 11 (8.9%) 13 (10.5%) 0.668
Vomiting 1 (0.8%) 1 (0.8%) 1.000
Skin rash 3 (2.4%) 6 (4.8%) 0.500
Fatigue 2 (1.6%) 5 (4.0%) 0.446




8 (6.5%) 15 (12.1%) 0.214
Adherence 116 (93.5%) 109 (87.9%) 0.125
*denotes significant difference.
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therapy also can be recommended in areas with high
clarithromycin or metronidazole resistance.
An ideal treatment for H. pylori infection should be highly ef-
fective, well tolerated, simple, and inexpensive. Fourteen-day re-
verse hybrid therapy is a simplified hybrid therapy with a
quadruple regimen in initial 7 days followed by a dual regimen
in final 7 days. The altered drug sequence of reverse hybrid regi-
men renders the treatment simpler to standard hybrid therapy. A
recent study showed that reverse hybrid therapy achieved a similar
eradication rate as hybrid therapy for H. pylori infection.29 While
both reverse hybrid therapy and concomitant therapy were simple
to administer, reverse hybrid therapy has lower frequencies of ab-
dominal pain and taste perversion than concomitant therapy, prob-
ably due to different durations of clarithromycin and
metronidazole exposure. With regard to the cost of therapies,
14-day reverse hybrid therapy was less expensive than 14-day
concomitant therapy (US dollars: 31.9 vs 45.2; Euros: 28.9 vs
41.6). The data suggest that 14-day reverse hybrid therapy is more
cost-effective than 14-day concomitant therapy in the first-line
treatment of H. pylori infection.
Because false-negative results can occur in patients taking anti-
biotics and PPI, we performed post-treatment evaluation for
H. pylori status 6 weeks after the end of eradication therapy in
the current study. This study has some limitations. First, current
work was not a double-blind placebo-controlled trial in which
the selection bias would be minimized. However, the application
of rapid urease test, histology, culture, and 13C-urea breath test to
assess the primary outcome was objective, and the staffs who per-
formed the tests were blind to the treatment groups. Second, the
number of H. pylori strains with antibiotic susceptibility data in
the reverse hybrid and concomitant groups was too small to make
a robust conclusion for the impacts of antibiotic resistances on the
eradication rates of each therapy. Nonetheless, this study is the first
trial comparing reverse hybrid therapy and concomitant therapy in
the treatment of H. pylori infection.
In conclusion, 14-day reverse hybrid therapy has comparable
eradication efficacy as 14-day concomitant therapy in the
first-line treatment of H. pylori infection. The former has fewer ad-
verse events and is cheaper than the latter.
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P value 0.192 0.226
Smoking
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P value 0.209 0.673
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Good 111/116 (95.7%) 102/109 (93.6%)
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P value — 1.000
Amoxicillin resistance
No 34/34 (100.0%) 38/39 (97.4%)
Yes — —
P value — —
HetEM, heterogeneous extensive metabolizer; HomEM, homogeneous
extensive metabolizer; PM, poor metabolizer.
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